A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD‐(L)1 in Patients With Advanced/Metastatic Non‐Small Cell Lung Cancer
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT In this Phase II study, 13 patients with stage IIIB/IV non‐small cell lung cancer with acquired resistance to immune checkpoint inhibitors were treated with tislelizumab, sitravatinib, and docetaxel. The efficacy and safety were evaluated. The combination treatment achieved median progression‐free survival of 7.6 months, median overall survival of 17.2 months, an objective response rate of 58.3% (1 not evaluable), and a disease control rate of 100%. Grade ≥ 3 treatment‐related adverse events were primarily neutropenia and leukopenia. Exploratory analyses showed a trend toward increased T cell receptor (TCR) diversity following treatment. High pre‐treatment CD8 + T cell polyfunctional strength index (PSI) showed a trend toward association with early treatment response and deeper tumor shrinkage, while CD8 + PSI decreased post‐therapy in responders, although not significantly. Larger changes in CD4 + T cell PSI were associated with longer PFS. Although these data indicate clinical benefit and immunologic correlates, the limited sample size precludes definitive conclusions. Furthermore, the observed changes in TCR and PSI dynamics are preliminary, hypothesis‐generating, and may provide insights for optimizing therapeutic strategies. However, validation via large‐scale, randomized controlled clinical trials remains warranted. Trial registration : Chictr.org.cn, ChiCTR2200065547. Registered in 2022‐11‐08, https://www.chictr.org.cn/showproj.html?proj=183439 .
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD‐(L)1 in Patients With Advanced/Metastatic Non‐Small Cell Lung Cancer
- Date Crossref
- 01/12/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Sichuan University Department of Pulmonary and Critical Care Medicine pays non établi dans la noticeUniversité ou école supérieure
-
West China Hospital of Sichuan University pays non établi dans la noticeÉtablissement de santé
-
Sichuan Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Affiliated Hospital of North Sichuan Medical College Department of Pulmonary and Critical Care Medicine pays non établi dans la noticeÉtablissement de santé
-
Institute Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology Chengdu China Department of Medical Oncology Sichuan Clinical Research Center for Cancer Sichuan Cancer Hospital & pays non établi dans la noticeUniversité ou école supérieure
Department of Pulmonary and Critical Care Medicine — Sichuan University, West China Hospital of Sichuan University et Sichuan Cancer Hospital, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.